John G. Kuhn

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang et al. · Neuro-Oncology · 2008 · 422 citations · Full text

Medicine, Neurology, Oncology +14

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy et al. · Investigational New Drugs · 2005 · 402 citations · Full text

Medicine, Neurology, Oncology +11

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 352 citations

Medicine, Oncology, Pharmacology +13

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

Igor Vivanco, H. Ian Robins, Daniel Rohle et al. · Cancer Discovery · 2012 · 344 citations · Full text

Medicine, Oncology, Pharmacology +16

EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy

Deliang Guo, Robert M. Prins, Julie Dang et al. · Science Signaling · 2009 · 344 citations · Full text

Life Sciences, Cell Biology, Pharmacology +9